Detail akcie Ovoca Gold online

Business Summary: Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Ovoca Bio PLC revenues was not reported. Net loss decreased 48% to EUR1.2M. Lower net loss reflects Bio-pharma segment loss decrease of 98% to EUR24K, Admin segment loss decrease of 60% to EUR388K. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.03 to -EUR0.01.